Cheung Thomas P, Xue Charlie, Leung Kelvin, Chan Kelvin, Li Chun G
The Chinese Medicine Research Group, Division of Chinese Medicine, RMIT University, Australia.
Clin Toxicol (Phila). 2006;44(4):371-8. doi: 10.1080/15563650600671712.
Certain frequently used Chinese herbal medicines commonly used for weight control, may contain toxic Aristolochia species, which have been associated with severe nephropathy and urothelial cancer in humans and animals. The toxic entities in Aristolochia species are aristolochic acid-I (AA-I) and aristolochic acid-II (AA-II). There is a lack of systematic information about the aristolochic acid content of Aristolochia species and related genera, including those in Chinese materia medica that are used in the treatment of overweight individuals.
To determine the content of AA-I and AA-II of commonly used Chinese herbal medicines (raw herbs and manufactured products) including species of Aristolochia and related genera.
Twenty-one raw herbs and seven manufactured herbal products were purchased from herbal wholesalers and traditional Chinese medicinal herb retailers in Melbourne, Australia in September 2003, after the supply of known aristolochic acid-containing herbs and products had been banned in Australia. Six additional raw herbs were sourced from a herbal teaching museum. These were purchased in 2001, before the prohibition. The contents of aristolochic acids of each was determined by high pressure liquid chromatography (HPLC), and confirmed by liquid chromatography-mass spectrometry (LC-MS).
Of the samples tested, four of the raw herbs purchased before the ban and two manufactured products purchased after the ban, were found to contain aristolochic acids (16-1002 ppm).
Several Chinese raw herbs and some commercially available manufactured herbal products contain aristolochic acids. The confusion in Chinese nomenclature for related raw herbs, and imprecise labelling of manufactured products may contribute to the inadvertent use of toxic herbal species in Chinese medicine practice. Additional measures are needed to ensure the safety of consumers of Chinese herbal medicines.
某些常用于控制体重的常用中草药可能含有有毒的马兜铃属植物,这些植物已在人类和动物中引发严重肾病和尿路上皮癌。马兜铃属植物中的有毒成分是马兜铃酸-I(AA-I)和马兜铃酸-II(AA-II)。关于马兜铃属植物及相关属(包括用于治疗超重个体的中药材中的植物)的马兜铃酸含量,缺乏系统性信息。
测定常用中草药(生药和制成品)中AA-I和AA-II的含量,这些中草药包括马兜铃属及相关属的植物。
2003年9月,在澳大利亚已禁止供应已知含马兜铃酸的草药和产品之后,从澳大利亚墨尔本的草药批发商和传统中药零售商处购买了21种生药和7种制成的草药产品。另外6种生药来自一个草药教学博物馆,这些是在禁令实施前的2001年购买的。通过高压液相色谱法(HPLC)测定每种草药的马兜铃酸含量,并通过液相色谱-质谱联用仪(LC-MS)进行确认。
在所测试的样品中,发现禁令实施前购买的4种生药和禁令实施后购买的2种制成品含有马兜铃酸(16 - 1002 ppm)。
几种中国生药和一些市售的制成草药产品含有马兜铃酸。相关生药的中文命名混乱以及制成品标签不精确,可能导致在中医实践中无意使用有毒草药品种。需要采取额外措施以确保中草药消费者的安全。